Indies Pharma Jamaica Limited (JMSE:INDIES)
Jamaica
· Delayed Price · Currency is JMD 2.800
-0.190 (-6.35%)
At close: Mar 5, 2026
Indies Pharma Jamaica Income Statement
Financials in millions JMD. Fiscal year is November - October.
Millions JMD. Fiscal year is Nov - Oct.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | 2020 - 2016 |
| Revenue | 1,126 | 1,159 | 1,055 | 937.28 | 846.83 | Upgrade
|
| Revenue Growth (YoY) | -2.82% | 9.81% | 12.61% | 10.68% | 10.56% | Upgrade
|
| Cost of Revenue | 457.76 | 465.82 | 417.41 | 323.44 | 329.81 | Upgrade
|
| Gross Profit | 668.56 | 693.15 | 638.05 | 613.84 | 517.02 | Upgrade
|
| Selling, General & Admin | 347.67 | 354.55 | 308.57 | 273.53 | 244.65 | Upgrade
|
| Other Operating Expenses | -8.04 | -6.41 | -4.23 | 1.15 | 1.5 | Upgrade
|
| Operating Expenses | 405.3 | 410.01 | 367.82 | 332.13 | 299.61 | Upgrade
|
| Operating Income | 263.27 | 283.15 | 270.24 | 281.71 | 217.41 | Upgrade
|
| Interest Expense | -62.71 | -64.46 | -66.78 | -60.48 | -68.96 | Upgrade
|
| Interest & Investment Income | 1.74 | 1.6 | 1.46 | 0.95 | 4.84 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.72 | 8.78 | 1.86 | -1.75 | 14.76 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.66 | -2.95 | -3.29 | -2.22 | -2.59 | Upgrade
|
| EBT Excluding Unusual Items | 200.37 | 226.12 | 203.48 | 218.21 | 165.47 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 1.55 | 3.07 | 1.88 | 2.4 | Upgrade
|
| Pretax Income | 200.37 | 251.77 | 217.63 | 220.79 | 167.87 | Upgrade
|
| Income Tax Expense | 19.08 | 30.6 | 4.58 | - | - | Upgrade
|
| Net Income | 181.29 | 221.18 | 213.06 | 220.79 | 167.87 | Upgrade
|
| Net Income to Common | 181.29 | 221.18 | 213.06 | 220.79 | 167.87 | Upgrade
|
| Net Income Growth | -18.04% | 3.81% | -3.50% | 31.53% | -19.04% | Upgrade
|
| Shares Outstanding (Basic) | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade
|
| Shares Outstanding (Diluted) | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade
|
| EPS (Basic) | 0.14 | 0.17 | 0.16 | 0.17 | 0.13 | Upgrade
|
| EPS (Diluted) | 0.14 | 0.17 | 0.16 | 0.17 | 0.13 | Upgrade
|
| EPS Growth | -18.04% | 3.81% | -3.50% | 31.53% | -19.04% | Upgrade
|
| Free Cash Flow | 320.3 | 241.13 | 265.45 | 288.85 | 325.76 | Upgrade
|
| Free Cash Flow Per Share | 0.24 | 0.18 | 0.20 | 0.22 | 0.24 | Upgrade
|
| Dividend Per Share | 0.135 | 0.110 | 0.110 | 0.113 | 0.110 | Upgrade
|
| Dividend Growth | 22.73% | - | -2.66% | 2.73% | -21.43% | Upgrade
|
| Gross Margin | 59.36% | 59.81% | 60.45% | 65.49% | 61.05% | Upgrade
|
| Operating Margin | 23.37% | 24.43% | 25.60% | 30.06% | 25.67% | Upgrade
|
| Profit Margin | 16.10% | 19.08% | 20.19% | 23.56% | 19.82% | Upgrade
|
| Free Cash Flow Margin | 28.44% | 20.80% | 25.15% | 30.82% | 38.47% | Upgrade
|
| EBITDA | 288.01 | 303.32 | 289.13 | 300.95 | 233.54 | Upgrade
|
| EBITDA Margin | 25.57% | 26.17% | 27.39% | 32.11% | 27.58% | Upgrade
|
| D&A For EBITDA | 24.74 | 20.17 | 18.9 | 19.24 | 16.13 | Upgrade
|
| EBIT | 263.27 | 283.15 | 270.24 | 281.71 | 217.41 | Upgrade
|
| EBIT Margin | 23.37% | 24.43% | 25.60% | 30.06% | 25.67% | Upgrade
|
| Effective Tax Rate | 9.52% | 12.15% | 2.10% | - | - | Upgrade
|
| Advertising Expenses | 11.52 | 10.72 | 5.27 | 4.98 | 6.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.